4-AcO-DiPT, also known as ipracetin, is a synthetic tryptamine with an acetoxy group at the 4-position and two isopropyl groups attached to the terminal nitrogen. It is the acetylated analogue of 4-HO-DiPT and belongs to the wider group of 4-substituted tryptamines related to psilocin. Laboratory studies have examined its serotonin-receptor activity and metabolism in human liver cells, although controlled human pharmacology remains limited.
Chemistry and identification
4-AcO-DiPT is 4-acetoxy-N,N-diisopropyltryptamine. Its structure combines the 4-acetoxyindole group with two bulky isopropyl substituents. It is distinct from 4-AcO-DPT, which has two n-propyl groups, and from 4-AcO-DMT, which has two methyl groups.
Forensic and research publications characterise it as a distinct tryptamine, not another name for its hydroxy analogue.
Receptor pharmacology
A 2023 study tested 4-AcO-DiPT at human serotonin receptors. In the 5-HT2A functional assay, it showed agonist activity with an EC50 of approximately 559 nM and efficacy slightly above the serotonin reference response. Its activity at 5-HT2C and 5-HT1A differed from its 5-HT2A profile, illustrating that the compound does not act identically across serotonin-receptor subtypes (Kozell and colleagues, 2023).
Metabolism
A 2022 study incubated 4-AcO-DiPT with pooled human hepatocytes and identified six metabolites after three hours. The main first step was ester hydrolysis, producing 4-HO-DiPT. Further transformations included N-dealkylation, N-oxidation, sulfation and glucuronidation. The authors proposed 4-HO-DiPT, 4-HO-iPT and 4-HO-DiPT-N-oxide as useful biomarkers for forensic detection (Malaca and colleagues, 2022).
The study used human hepatocytes, which provide a useful model of liver metabolism, but it was not a controlled administration study in people. It therefore cannot establish the timing or relative importance of each pathway in vivo.
Reported effects and clinical evidence
Human reports are limited and largely anecdotal. Descriptions sometimes compare the compound with 4-HO-DiPT or other 4-substituted tryptamines, but there is no controlled study establishing a reliable subjective profile, duration or adverse-event frequency.
Toxicity and research limitations
The available studies establish receptor activity and several metabolic pathways, but not a human toxic range or long-term safety profile. The detection of hydroxy and conjugated metabolites may assist forensic analysis, particularly when the parent compound is no longer present.
Clinical findings for 4-HO-DiPT or 4-AcO-DMT cannot be applied directly to 4-AcO-DiPT. Differences in the ring substituent, terminal nitrogen groups, or both can influence receptor activity and metabolism.
Related tryptamines
4-AcO-DiPT is related to 4-HO-DiPT, 4-AcO-DMT, 4-AcO-DET and 4-AcO-MiPT. Its two isopropyl groups distinguish it from the other compounds in this group.
